Nonsyndromic congenital nail disorder 5

Summary

Nonsyndromic congenital nail disorder 5 (MONDO:0008125) is a disease. A subtype of inherited isolated nail anomaly — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	nonsyndromic congenital nail disorder 5
Mondo ID	MONDO:0008125
MeSH	C563503
OMIM	164800
DOID	DOID:0080083
UMLS	C1833909
MedGen	318994
GARD	0024602
Is cancer (heuristic)	no

Also known as: nail disorder, nonsyndromic congenital, 5 · NDNC5 · nonsyndromic congenital nail disorder type 5

Disease family

This is a subtype of inherited isolated nail anomaly. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › nail disorder › inherited isolated nail anomaly › nonsyndromic congenital nail disorder 5

Related subtypes (8): isolated congenital digital clubbing, nonsyndromic congenital nail disorder 2, nonsyndromic congenital nail disorder 3, nonsyndromic congenital nail disorder 1, nonsyndromic congenital nail disorder 7, nonsyndromic congenital nail disorder 8, leukonychia totalis, isolated congenital anonychia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.